Front. Mol. Neurosci. Frontiers in Molecular Neuroscience Front. Mol. Neurosci. 1662-5099 Frontiers Media S.A. 10.3389/fnmol.2023.1125087 Molecular Neuroscience Review Advances in neurexin studies and the emerging role of neurexin-2 in autism spectrum disorder Khoja Sheraz † Haile Mulatwa T. † Chen Lulu Y. * Department of Anatomy and Neurobiology, School of Medicine, University of California, Irvine, Irvine, CA, United States

Edited by: Katsuhiko Tabuchi, Shinshu University, Japan

Reviewed by: Stephan Maxeiner, Saarland University, Germany; Davide Comoletti, Victoria University of Wellington, New Zealand

 *Correspondence: Lulu Y. Chen, chenly@uci.edu

†These authors have contributed equally to this work and share first authorship

This article was submitted to Neuroplasticity and Development, a section of the journal Frontiers in Molecular Neuroscience

 27 02 2023 2023 16 1125087 15 12 2022 08 02 2023 Copyright © 2023 Khoja, Haile and Chen. 2023 Khoja, Haile and Chen

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Over the past 3 decades, the prevalence of autism spectrum disorder (ASD) has increased globally from 20 to 28 million cases making ASD the fastest-growing developmental disability in the world. Neurexins are a family of presynaptic cell adhesion molecules that have been increasingly implicated in ASD, as evidenced by genetic mutations in the clinical population. Neurexins function as context-dependent specifiers of synapse properties and critical modulators in maintaining the balance between excitatory and inhibitory transmission (E/I balance). Disrupted E/I balance has long been established as a hallmark of ASD making neurexins excellent starting points for understanding the etiology of ASD. Herein we review neurexin mutations that have been discovered in ASD patients. Further, we discuss distinct synaptic mechanisms underlying the aberrant neurotransmission and behavioral deficits observed in different neurexin mouse models, with focus on recent discoveries from the previously overlooked neurexin-2 gene (Nrxn2 in mice and NRXN2 in humans). Hence, the aim of this review is to provide a summary of new synaptic insights into the molecular underpinnings of ASD.

 synapses autism spectrum disorder synaptic signaling neurexins excitatory/inhibitory balance synaptopathy genetics social behavior GF15247 School of Medicine10.13039/100008235 Introduction

Autism spectrum disorder (ASD) is characterized by two core criteria according to the Diagnostic and Statistical Manual of Mental Disorders criteria: (1) impaired social communication and interaction, and (2) restricted and repetitive interests and behaviors (Landa, 2008; Lai et al., 2014; Rylaarsdam and Guemez-Gamboa, 2019). ASD is the leading cause of disability for children under 5 in the world (Baxter et al., 2015). The Autism and Developmental Disabilities Monitoring (ADDM) Network reported a significant increase in prevalence of ASDs among children from 1 in 150 in 2000–2002 to 1 in 68 in 2010–2012 (Autism and Developmental Disabilities Monitoring Network Surveillance Year 2008 Principal Investigators and Centers for Disease Control and Prevention, 2012; ADDM and CDC, 2014; Christensen et al., 2016) and then to 1 in 44 in 2018 (Maenner et al., 2021) in the US, emphasizing the importance of increased scientific research. The prevalence of ASD is more common in males over females with a ratio of 4:1 (Christensen et al., 2016; Baio et al., 2018). ASD require life-long support of special educational and social services with an estimated cost of $461 billion by 2025 (Lavelle et al., 2014; Leigh and Du, 2015), thus imposing a major societal and economic burden in the US. Over 70% of individuals with ASD have concurrent conditions; among these 45% have intellectual disability, 14–38% have tic disorders, 8–30% have epilepsy, 5% have genetic syndromes (i.e., Fragile X, Rett syndrome, Angelman syndrome etc.), 50–80% have sleep disorders, 42–56% have anxiety, 12–70% have depression, and up to 32% have various personality disorders (Lai et al., 2014). Given that ASD is a multifactorial and complex disorder, it is currently believed that it occurs due to a combination of genetic and environmental risks that either directly or indirectly affect synapses (Persico and Bourgeron, 2006; Spooren et al., 2012; Bourgeron, 2015; Masini et al., 2020). The rising prevalence, economic and social hardships, and co-morbidity with other neurological disorders emphasizes the need to better understand the pathophysiology at the genetic and cellular level, in order to discover drug targets and develop effective therapeutic interventions.

Genetic causes have been reported to contribute to 25% of ASD cases (Huguet et al., 2013). Studies have attributed a strong genetic component to the pathophysiology of ASD as evidenced by a high concordance rate of 82–90% in monozygotic twins, compared with 1–10% in dizygotic twins and 2–3% in siblings (Folstein and Rosen-Sheidley, 2001; Veenstra-Vander Weele and Cook, 2004). 10–25% of ASD cases have an underlying genetic disorder such as Fragile X, tuberous sclerosis complex, or Rett syndrome (Carter and Scherer, 2013). Genome-wide association studies and next generation sequencing have made significant breakthroughs in our understanding of ASD by identifying short insertions or deletions, copy number variants (CNVs), single nucleotide variants (SNVs) and single nucleotide polymorphisms (SNPs). CNVs have been reported to occur at a rare frequency in ASD with 3% of ASD cases associated with recurrent CNVs (Bourgeron, 2016) and 4–10% of ASD cases with de novo CNVs (Sebat et al., 2007; Pinto et al., 2010). SNVs have been found to occur in 7% of ASD cases (Masini et al., 2020).

Several of the ASD-candidate genes, identified through gene testing techniques, have a critical role in synapse assembly, transmission, and plasticity. To this end, numerous investigations have identified genetic mutations in synaptic cell adhesion molecules (SAMs) responsible for mediating trans-synaptic signaling, shaping synapse properties, and defining the characteristics of neural networks (Chih et al., 2005; de Wit et al., 2009; Siddiqui et al., 2010; Aoto et al., 2013; Pettem et al., 2013; Anderson et al., 2015; Aoto et al., 2015; Luo et al., 2021). SAMs are integral to organizing synaptic junctions, mediating synaptic transmission and plasticity (Missler et al., 2012; Jang et al., 2017; Südhof, 2018; Kim et al., 2021; Südhof, 2021). Synapses are the most fundamental structures that connect neurons into circuits by enabling the transfer of information, while simultaneously processing this information during transfer; thus governing cognition and behavior (Williams et al., 2010; Bargmann, 2012; Bargmann and Marder, 2013; Di Cristo and Chattopadhyaya, 2020; Sanes and Zipursky, 2020). Normal brain development is accompanied by dynamic synaptic changes which regulate a balance of excitatory glutamatergic and inhibitory GABAergic neuronal firing (E/I balance). E/I imbalances in key cortical and subcortical neural circuits have been proposed as an etiological mechanism underlying ASD (Rubenstein and Merzenich, 2003; Oliveira et al., 2018; Port et al., 2019; Culotta and Penzes, 2020). To this end, numerous studies have reported altered levels of glutamate (Shinohe et al., 2006; Carlson, 2012; He et al., 2021) and/or GABA levels in ASD patients (Fatemi et al., 2010; Robertson et al., 2016; Schür et al., 2016). Considering their critical role in neurotransmission, SAMs are key players involved in excitatory and inhibitory synapse assembly and transmission and hence, are integral to modulating the E/I balance. The discovery of novel genetic mutations in SAMs plays an essential role in elucidating of specific pathways and mechanisms associated with ASD endophenotypes, which can aid in the development of druggable targets at synapses. These investigations are important considering the heterogeneity in the severity and magnitude of core ASD phenotypes, which makes diagnoses challenging and limits pharmacotherapeutic options.

Neurexins are multifaceted representatives of presynaptic SAMs that interact with a wide variety of postsynaptic partners (neuroligins, dystroglycans, cerebellins, and LRRTMs) in mediating diverse synaptic functions including synapse assembly (Graf et al., 2004; Nam and Chen, 2005; Kang et al., 2008), presynaptic release machinery (Dean et al., 2003; Anderson et al., 2015; Luo et al., 2020), postsynaptic receptor signaling, and synaptic function (Aoto et al., 2013, 2015; Chen et al., 2017; Luo et al., 2021). The mammalian genome contains three neurexin genes (Nrxn1, Nrxn2, Nrxn3 in mice; and NRXN1, NRXN2, NRXN3 in humans), and each gene contains two different promoters initiating neurexin gene transcription from two different sites referred to as α-neurexins with longer coding sequences and therefore, larger membrane-tethered moieties, and β-neurexins with shorter sequences and consequently smaller membrane-tethered moieties (Ushkaryov et al., 1992; Ushkaryov and Südhof, 1993; Ushkaryov et al., 1994). Neurexin-1 gene has an additional promoter which initiates neurexin gene transcription of γ-neurexin with the shortest sequence and smallest membrane-tethered moiety. The extracellular sequence of Nrxn1γ contains only the juxtamembranous threonine rich residues and cysteine-loop sequences of Nrxn1α and Nrxn1β but not the typical extracellular neurexin sequences (Sterky et al., 2017). An intriguing feature of neurexins is that they can undergo extensive alternative splicing at six canonical sites (referred to as SS1-SS6), leading to generation of thousands of splice variants, each of which is capable of conferring specific synaptic properties (Ullrich et al., 1995; Missler and Südhof, 1998; Tabuchi and Südhof, 2002). Neurexins have been exceedingly implicated in neuropsychiatric disorders, especially ASD and its comorbidities. In humans each of the three neurexin genes have been implicated in ASD [NRXN1 (Kim et al., 2008; Marshall et al., 2008; Glessner et al., 2009; Onay et al., 2016; Ishizuka et al., 2020); NRXN2 (Gauthier et al., 2011; Mohrmann et al., 2011; Wang et al., 2018); NRXN3 (Vaags et al., 2012; Wang et al., 2018; Yuan et al., 2018)]. At the preclinical level, mouse models have shown that deletion of neurexin genes induced behaviors reminiscent of ASD phenotypes [Nrxn1 (Etherton et al., 2009; Grayton et al., 2013; Rabaneda et al., 2014; Armstrong et al., 2020); Nrxn2 (Dachtler et al., 2014; Born et al., 2015; Dachtler et al., 2015; Haile et al., 2022)]. Understanding the role of neurexins in synaptic signaling will substantially improve ASD prognosis. The present review focuses on current findings in neurexins that have advanced our understanding of ASD, with particular emphasis on NRXN2 as an emerging ASD risk gene candidate.

 Neurexin mutations associated with human ASD patients

According to the ClinVar database, provided by the National Center for Biotechnology Information for collecting genotype–phenotype relationships in the human genome, over 19,000 patients with ASD have one or more genetic mutations in over 18,000 different genes (ClinVar, Supplementary Data). This is especially important because recent work showed that there are 20,000 protein coding genes in the human genome suggesting the increased risk for ASD in the human population (Nurk et al., 2022). The abundance of gene mutations found in patients with ASD may contribute to the diverse variation in the clinical manifestation of ASD. Among these, 0.08% of total reports are those in presynaptic neurexins alone, and 0.16% in either neurexins or neuroligins. Given the considerable number of mutations linking neurexins to ASD, longitudinal studies are required to fully understand how these mutations may lead to a predisposition to ASD.

NRXN1 and NRXN3

To date 1,756 mutations in the NRXN1 gene have been reported in humans. Among these, 0.5% are in patients with ASD. Several studies (Kim et al., 2008; Marshall et al., 2008; Zahir et al., 2008; Glessner et al., 2009; Onay et al., 2016; Ishizuka et al., 2020) provide evidence that single point mutations and CNVs in NRXN1, found in human patients with ASD, can lead to pleiotropic effects. Fewer studies have investigated NRXN3 mutations in human ASD patients (Vaags et al., 2012; Wang et al., 2018; Yuan et al., 2018). According to ClinVar, 39 mutations in NRXN3 have been reported in patients, and 10% are in patients with ASD.

 NRXN2

NRXN2 gene was not implicated in ASD in the literature or any disorder until 2011, almost 20 years from the initial discovery of the gene (Gauthier et al., 2011; Mohrmann et al., 2011). Gauthier et al. identified a truncating mutation in exon 12 of NRXN2 in a patient with ASD, who inherited this mutation from a father with severe language delay and a family history of schizophrenia. Gauthier et al. engineered this mutation and transfected it into COS cells. They discovered that this mutation was causing a failure of Nrxn2 to anchor into the plasma membrane and was unable to bind postsynaptic binding partners Lrrtm2 or Nlgn2 in cell binding assays. Since then, other studies have observed de novo deletions in NRXN2 gene in human patients with ASD, including one missing a chromosomal region spanning the entire NRXN2 gene that was suspected to be associated with the patient’s autistic traits and neurodevelopmental delay (Mohrmann et al., 2011), the other was identified in a patient exhibiting autistic behavior and severe intellectual disability with a 1.6 Mb deletion at the NRXN2 locus (Boyle et al., 2015). Other reports have also identified NRXN2 mutations in human patients, including a more recent study of a patient containing heterozygous variants in NRXN1 and NRXN2 genes, with early infantile epileptic encephalopathy (EIEE; Rochtus et al., 2019). This patient inherited the NRXN2 mutation from a father with a family history of febrile seizures. Currently, according to ClinVar, a total of 120 mutations have been identified, and among those, 5% have ASD, 5% have intellectual disability, and 2.5% have epilepsy (Supplementary Data).

Mutations in all three neurexin genes have been found in disorders comorbid with autism such as epilepsy (Tuchman et al., 2010; Jeste and Tuchman, 2015), indicating that neurexin mutations may represent a common genetic mechanism underlying autism-epilepsy co-morbidity. Thus, investigating the synaptic significance of neurexins in circuitries regulating behavioral functions (cognition, information processing, and emotional responses) can be a stepping stone towards unraveling the etiology of these disorders and developing therapeutic intervention.

 Neurexin mediated regulation of synaptic density and transmission Nrxn1αβ, Nrxn2αβ, and Nrxn3αβ

Since their initial discovery as type I membrane receptors for α-latrotoxin, a spider toxin known to induce excessive synaptic vesicle exocytosis resulting in neuromuscular paralysis (Ushkaryov et al., 1992; Ushkaryov and Südhof, 1993; Ushkaryov et al., 1994), several studies have shown that neurexins play critical roles in diverse synaptic functions including synapse assembly (Missler et al., 2003; Nam and Chen, 2005; Luo et al., 2020), presynaptic release machinery (Missler et al., 2003; Anderson et al., 2015; Aoto et al., 2015; Chen et al., 2017; Luo et al., 2020, 2021), and postsynaptic receptor signaling (Missler et al., 2003; Aoto et al., 2013, 2015; Chen et al., 2017).

Initial studies using constitutive deletion approach provided the first evidence that α-neurexins are required for postnatal survival. Homozygous deletion of Nrxn1/2/3 (only α-neurexins) reduced presynaptic Ca2+ influx, number of GABAergic terminals, and reduced spontaneous and evoked neurotransmitter release in neocortical neurons (Missler et al., 2003) and at the neuromuscular junctions (Sons et al., 2006). Further studies using homozygous Nrxn1/2/3α knockout (KO) mouse model showed that they regulate N and P/Q type Ca2+ channels (Zhang et al., 2005) and are required for normal NMDA receptors (NMDARs) function (Kattenstroth et al., 2004). The role of neurexins in regulating neurotransmission through coupling of presynaptic calcium channels to release sites was later discovered by using a conditional KO (cKO) approach deleting Nrxn1/2/3 (all α-and β-neurexins) (referred to as “pan-Nrxn cKO” approach) at the Calyx of Held synapses (Luo et al., 2020). Our understanding of neurexins was greatly enhanced when the conditional KO approach became available and allowed for postnatal survival with both spatial and temporal controls. Studies using a cKO approach of Nrxn1/2/3 (only β-neurexins) showed that they regulate postsynaptic endocannabinoid signaling through suppressing CB1 receptor agonist 2AG synthesis in hippocampal synapses (Anderson et al., 2015). Interestingly, despite the low expression of β-neurexins (10- to 100-fold lower than that of α-neurexins), cKO of Nrxn1/2/3 (only β-neurexins) lead to a two-fold decrease in three excitatory synapse parameters: (1) EPSC amplitude, (2) release probability, and (3) action potential induced Ca2+ influx (Anderson et al., 2015).

Recent work has reported that neurexins are required for presynaptic GABAB receptor signaling (Luo et al., 2021). The study employed a pan-Nrxn cKO approach in four central synapses: excitatory Calyx of Held synapses in the brainstem, excitatory and inhibitory synapses in pyramidal neurons in the CA1 region of the hippocampus, and inhibitory basket cell synapses in the cerebellum, thus showing that neurexins universally regulate presynaptic GABAB-receptor signaling, albeit at different magnitude between synapses (Luo et al., 2021). More recent work shows that neurexins regulate GABA co-release in dopamine (DA) neurons (Ducrot et al., 2021). The pan-Nrxn cKO approach in DA neurons, showed (1) region-specific increase in GABA release from DA terminals (increase in the ventral but not in the dorsal striatum) and (2) slower DA reuptake along with decreased and increased densities of DA transporter (DAT) and vesicular monoamine transporter (VMAT2), respectively (Ducrot et al., 2021), indicating that neurexins support the functional but not the structural aspect of DA neuron synapses. Utilization of the conditional deletion approach has enabled significant progress in our understanding of neurexins’ function in specific synapses (Ducrot et al., 2021; Luo et al., 2021). This is important because the first study using the pan-Nrxn cKO approach in various types of synapses discovered severe, but dramatically different phenotypes (Chen et al., 2017). This study showed that ablation of neurexins from parvalbumin-positive interneurons in the prefrontal cortex caused a loss of synapses without any effect on action-potential induced Ca2+ influx, or synaptic strength. The same study revealed that ablation of neurexins from somatostatin-positive interneurons in the same brain region impaired action-potential induced Ca2+ influx and decreased synaptic strength without changes in number of synapses (Chen et al., 2017). This shows that conditional deletion of neurexins induced two different synaptic phenotypes in two inhibitory presynaptic neurons that target the same postsynaptic neuron. Taken together, these studies indicate that neurexins promote the functional properties, but not the physical assembly and organization of synapses. Additionally, these findings suggest that neurexins do not perform canonical functions at the synapses that are generalized, universal functions across all synapses. Instead, neurexins can perform distinct functions in different synapses and hence, they should be investigated in a cell-type and circuit-specific manner (Table 1).

Summary table of synaptic transmission examined in neurexin mutant mouse models.

Neurexin targeted in mouse models Brain region examined Genetic approach/manipulation Main findings in synaptic function References
Nrxn1α, β, or αβ Cortex1, Hippocampus2,3 Conditional KO1 Nrxn1β KO decreased mEPSCs and mIPSCs frequency in cortical layer 5/6 pyramidal neurons1 Rabaneda et al.(2014)1
Constitutive KO2 Nrxn1α KO reduced spontaneous release in excitatory glutamatergic synapses without any effect on inhibitory transmission in pyramidal neurons in the CA1 region of the hippocampus2 Etherton et al. (2009)2
Conditional KI3 Conditional KI of SS4+ in Nrxn1 increased NMDARs-mediated EPSCs without affecting AMPARs-mediated EPSCs in the CA1-subiculum synapses in the hippocampus3 Dai et al. (2019)3
Nrxn2α, β, or αβ Hippocampus3,5,6 Conditional KI3 Conditional KI of SS4+ in Nrxn2 lead to no change in NMDAR and AMPAR-mediated EPSCs3 Dai et al. (2019)3
Cortex4 Constitutive KO4,5 Constitutive KO of Nrxn2α and Nrxn2αβ reduced spontaneous transmitter release at excitatory synapses in the neocortex. Both KO mice exhibited altered facilitation and NMDAR function due to a reduction in NMDAR-dependent decay time and responses in excitatory synapses. Inhibitory transmission and synapse densities and ultrastructure remained unchanged in both Nrxn2α and Nrxn2αβ KO4 Born et al. (2015)4
Conditional KO5,6 Constitutive deletion of Nrxn2 gene increases hippocampal CA3 to CA1 synaptic connections. Conditional (Neuron-specific) deletion of Nrxn2 gene also increases CA3 to CA1 synaptic connectivity, and release probability, and increases excitatory synapse density in the CA1 region5 Lin et al. (2023)5
Conditional (Emx1Cre driven) deletion of Nrxn2 gene increased network activity in hippocampal circuities as measured by increased sEPSC and sIPSC frequencies independent of changes in neurotransmitter release probability or changes in AMPARs and NMDARs contributions6 Haile et al. (2022)6
Nrxn3α, β, or αβ Hippocampus3,7 Conditional KI3 Conditional KI of SS4+ in Nrxn3 suppressed AMPARs-mediated synaptic responses without any effect on NMDARs function in the same synapses3 Dai et al. (2019)3
Constitutive KI7 Constitutive KI of SS4+ in Nrxn3 caused a decrease in AMPARs mediated synaptic responses in hippocampal synapses7 Aoto et al. (2013)7
Olfactory bulb8 Conditional KO8 Conditional deletion of Nrxn3 gene in the CA1 region of the hippocampus decreased (AMPARs)-mediated excitatory response and blockade of NMDARs-mediated LTP. In olfactory bulb synapses however, conditional deletion of Nrxn3 gene decreased GABAergic mediated inhibitory responses8 Aoto et al. (2015)8
Nrxn123α, β, or αβ Cortex9,11, Hippocampus12,14 Brain Stem9,10,13,14 Cerebellum 11,14 Striatum15 Constitutive KO9,10 Constitutive deletion of Nrxn1/2/3 (only α-neurexins) reduced presynaptic Ca2+ influx, number of GABAergic terminals, and reduced spontaneous and evoked neurotransmitter release in neocortical neurons9 Missler et al. (2003)9
Constitutive KO Nrxn1/2/3 (only α-neurexins) showed that they regulate N and P/Q type Ca2+ channels10 Zhang et al. (2005)10
Conditional KO11,12,13,14,15 Conditional ablation of neurexins from parvalbumin-positive interneurons in the prefrontal cortex caused a loss of synapses without any effect on action-potential induced Ca2+ influx, or synaptic strength. Conditional ablation of neurexins from somatostatin-positive interneurons in the same brain region impaired action-potential induced Ca2+ influx and decreased synaptic strength without changes in number of synapses11 Chen et al. (2017)11
Conditional KO of Nrxn1/2/3 (only β-neurexins) showed that they regulate postsynaptic endocannabinoid signaling through suppressing CB1 receptor agonist 2AG synthesis in hippocampal synapses. Despite the low expression of β-neurexins, cKO of Nrxn1/2/3 (only β-neurexins) lead to a two-fold decrease in EPSC amplitude, release probability, and action potential induced Ca2+ influx12 Anderson et al. (2015)12
Conditional KO of Nrxn1/2/3 (all α-and β-neurexins) at the Calyx of Held synapses revealed neurexins regulate neurotransmission through coupling of presynaptic calcium channels to release sites13 Luo et al. (2020)13
Conditional KO of Nrxn1/2/3 (all α-and β-neurexins) from four central synapses: excitatory Calyx of Held synapses in the brainstem, excitatory and inhibitory synapses in pyramidal neurons in the CA1 region of the hippocampus, and inhibitory basket cell synapses in the cerebellum, showed that neurexins universally regulate presynaptic GABAB-receptor signaling, albeit at different magnitude between synapses14 Luo et al. (2021)14
Conditional KO of Nrxn 1/2/3 (all α-and β-neurexins) in DA neurons, showed (1) region-specific increase in GABA release from DA terminals (increase in the ventral but not in the dorsal striatum) and (2) slower DA reuptake along with decreased and increased densities of DAT and VMAT2, respectively15 Ducrot et al. (2021)15

KO, knockout; KI, knockin; mEPSCs, miniature excitatory postsynaptic currents; mIPSCS, miniature inhibitory postsynaptic currents; NMDARs, N-Methyl-D-aspartate receptors; AMPARs, α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors; EPSCs, excitatory postsynaptic currents; sEPSCs, spontaneous excitatory postsynaptic currents; sIPSCs, spontaneous inhibitory postsynaptic currents; LTP, long-term potentiation; GABA, γ-aminobutyric acid; DA, dopamine; DAT, dopamine transporter; VMAT2, vesicular monoamine transporter-2. Superscript numbers listed under “brain region examined”; “Genetic approach/manipulation” and “Main findings in synaptic function” corresponds to the respective study listed under “References.”

 Nrxn1αβ and Nrxn3αβ

Individual neurexin gene deletions have further attested to the diverse and non-canonical role of neurexins at synapses. Homozygous deletion of Nrxn1 (only α-neurexins) significantly reduced spontaneous release in excitatory glutamatergic synapses without any effect on inhibitory transmission in pyramidal neurons in the CA1 region of the hippocampus (Etherton et al., 2009). Consistent with pan-Nrxn cKO approach, conditional deletion of Nrxn3 gene in two different regions (CA1 region of the hippocampus and in the olfactory bulb) resulted in two distinct phenotypes (Aoto et al., 2015). Conditional deletion of Nrxn3 gene in the CA1 region of the hippocampus decreased AMPA receptors (AMPARs)-mediated excitatory response and blockade of NMDARs-mediated LTP. In olfactory bulb synapses however, conditional deletion of Nrxn3 gene decreased GABAergic mediated inhibitory responses (Aoto et al., 2015). Enforcement to constitutively include splice site 4 (SS4+) (a splice site shared by all neurexin transcripts), in Nrxn3 caused a decrease in AMPARs mediated synaptic responses in hippocampal synapses (Aoto et al., 2013). Inclusion of SS4+ in Nrxn1 increased NMDARs-mediated EPSCs without affecting AMPARs-mediated EPSCs in the CA1-subiculum synapses in the hippocampus. On the other hand, Nrxn3SS4+ suppressed AMPARs-mediated synaptic responses without any effect on NMDARs function in the same synapses (Dai et al., 2019). Taken together these studies suggest that Nrxn1 and Nrxn3 have distinct regulatory roles that are synapse specific (Table 1).

 Nrxn2

Since the discovery of the neurexin genes, an increasing number of findings suggest that neurexin-2 gene is distinct from neurexin-1 and neurexin-3 genes. Phylogenetic analysis (Reissner et al., 2013) suggest that neurexin-2 gene diverged from a common progenitor of neurexin-1 and neurexin-3 genes indicating that neurexin-1 and neurexin-3 genes are more closely related to each other than to neurexin-2 gene. NRXN1 and NRXN3 genes are unusually long genes (>1 Mbp) while NRXN2 gene is only 0.117 Mbp (Rowen et al., 2002; Tabuchi and Südhof, 2002). The smaller length of NRXN2 gene can underlie its unique expression pattern in the developing human cerebral cortex that is distinct from NRXN1 and NRXN3. A study that analyzed human cortical tissue by qRT-PCR at 8–12 postconceptional weeks showed that mRNA levels of NRXN2 were higher than those of NRXN1 and NRXN3 during early stages of brain development (Harkin et al., 2017). The same study showed that NRXN2 localized with markers of axon growth and presynaptic terminals in proliferative layers of the developing cortex indicating a role for NRXN2 in early cortical synaptogenesis (Harkin et al., 2017). Furthermore, mouse studies have shown that Nrxn1 and Nrxn3 genes have six different homologous splice sites producing thousands of splice variants while Nrxn2 gene lacks the sixth splice site (Treutlein et al., 2014). A study showed that inclusion or exclusion of SS4 in Nrxn1 and Nrxn3 regulated AMPARs and NMDARs, whereas inclusion or exclusion of SS4 in Nrxn2 had no effect on AMPARs and NMDARs (Dai et al., 2019). Overall, these studies demonstrate that neurexin-2 gene is distinct from neurexin-1 and neurexin-3 genes across different mammalian species.

Until very recently, only three published studies employed genetic mouse models with constitutive KO to study Nrxn2 (Dachtler et al., 2014; Born et al., 2015; Dachtler et al., 2015). From these studies, it was shown that Nrxn2α and Nrxn2αβ KO mice exhibited reduced spontaneous transmitter release at excitatory synapses in the neocortex (Born et al., 2015). Additionally, both KOs exhibited altered facilitation and NMDAR function due to a reduction in NMDAR-dependent decay time and responses in excitatory synapses (Born et al., 2015). Inhibitory transmission and synapse densities and ultrastructure remained unchanged in both Nrxn2α and Nrxn2αβ KO (Born et al., 2015). Nrxn2α KO mice had significant decreases in mRNA of genes encoding for proteins involved in both excitatory and inhibitory transmission as well as in Munc18-1 in the hippocampus (Dachtler et al., 2015). More recently, (Pervolaraki et al., 2019) used diffusion tensor MRI in optically cleared brain tissue from Nrxn2α KO mice and discovered altered microstructure and structural connectivity patterns in the cortex, hippocampus and amygdala, that are brain regions implicated in ASD (Pervolaraki et al., 2019).

While these studies are informative, they do not address the synapse specificity required to effectively study Nrxn2. Moreover, the Nrxn2αβ mouse model by Born et al. (Born et al., 2015) was never able to show complete deletion of Nrxn2 gene, and the mouse generated was later abandoned because there was no clear evidence that Nrxn2 gene was deleted (Lin et al., 2023). The first study to comprehensively examine Nrxn2 employed constitutive, conditional and neuron-specific deletion strategies. Neuron-specific deletion of Nrxn2 was employed to account for glial contributions to synaptic phenotypes. Lin et al. discovered (1) the constitutive deletion of Nrxn2 gene increased hippocampal CA3 to CA1 synaptic connections, (2) neuron-specific deletion of Nrxn2 gene increased CA3 to CA1 synaptic connectivity, release probability, and excitatory synapse density in the CA1 region, (3) conditional deletion of Nrxn2 gene enhanced CA3 to CA1 synaptic connections (Lin et al., 2023). Taken together, this comprehensive study suggests that Nrxn2 regulates synaptic connectivity by restricting excitatory synaptic connections in hippocampal circuits. These exciting findings indicate that functions of Nrxn2 are distinct from those of Nrxn1 and Nrxn3 wherein Nrxn1 and Nrxn3 promote synaptic function and Nrxn2 restricts synaptic function in the hippocampus.

Findings from Lin et al. (2023) showed that Nrxn2 regulates synaptic connectivity by inhibiting excitatory synaptic connections in hippocampal circuits. Whether excitatory or inhibitory neuron specific Nrxn2 regulates this restrictive function on excitatory synapses remains unclear. A recent study involved deletion of Nrxn2 gene under the Emx1Cre promoter (Haile et al., 2022) which is predominately expressed in excitatory neurons of neocortex and hippocampus (Boncinelli et al., 1995; Gorski et al., 2002). Emx1Cre driven deletion of Nrxn2 gene increased network activity in hippocampal circuities as measured by increased sEPSC and sIPSC frequencies independent of changes in neurotransmitter release probability or changes in AMPARs and NMDARs contributions (Haile et al., 2022). There was an increase in number of immature spines with no changes in mature spines or dendritic branching in the CA1 region of the hippocampus or cellular layers in the cortex. Although previous studies have shown a canonical regulatory role of neurexins on presynaptic GABAB receptors (Luo et al., 2021), Emx1Cre driven deletion of Nrxn2 gene showed that Nrxn2 might not share this canonical role (Haile et al., 2022). Most intriguingly, the group observed spontaneously reoccurring electrographic and behavioral seizures which have previously never been demonstrated in any other mutant mouse models for neurexins to date (Haile et al., 2022).

 Behavioral abnormalities in <italic>Neurexin</italic> mutant mouse models relevant to ASD Nrxn1αβ, Nrxn2αβ, and Nrxn3αβ

The effects of a conditional deletion of all three neurexin genes within specific circuits in the hippocampus or striatum on behavioral regulation has been investigated to some extent. Conditional deletion of Nrxn1/2/3 (only β-neurexins) in the hippocampal CA1 region impaired contextual memory without any impairments in cue-dependent memory (Anderson et al., 2015). In another study, the pan-Nrxn cKO approach in DA neurons reduced amphetamine-induced locomotor activity without affecting other striatal-dependent behaviors such as motor coordination or sucrose preference. This investigation suggests that DAT-IRES-Cre driven deletion of neurexin genes can impair DAT function (expressed on DA neurons) leading to altered behavioral responses to DA-acting drugs (Ducrot et al., 2021).

 Nrxn1 and Nrxn3 KO mouse models

Constitutive deletion of Nrxn1 (only α-neurexins) induced ASD-related typical (social behavior, communication, repetitive behavioral patterns) and associated (anxiety, cognition) behavioral symptoms (Etherton et al., 2009; Grayton et al., 2013; Dachtler et al., 2015; Armstrong et al., 2020). Certain ASD-behavioral deficits (social approach, anxiety, locomotor activity) were reported from Nrxn1α KO mice on a pure genetic background (Grayton et al., 2013; Armstrong et al., 2020), but not on a mixed background (Etherton et al., 2009; Dachtler et al., 2015), suggesting the importance of transferring the allele to a pure genetic background to understand its role in disease pathophysiology. Furthermore, a mixed genetic background can influence regions outside of the targeted locus, thus confounding behavioral assessment (Reichelt et al., 2012). Conditional deletion approaches have also been employed in studying the role for Nrxn1 in behavioral regulation. Conditional deletion of Nrxn1 (only β-neurexins) from excitatory forebrain neurons in mice induced social approach deficits and repetitive behavioral patterns (Rabaneda et al., 2014). Constitutive absence of Nrxn1 (SS4-) transcripts in the hippocampal CA1 region induced spatial and contextual memory deficits (Dai et al., 2019). Despite the presence of NRXN3 mutations in ASD, there are no comprehensive investigations that have been undertaken in constitutive Nrxn3 KO mice. To date, a conditional approach has been employed in which deletion of Nrxn3 gene from the inhibitory granule cells of the olfactory bulb increased the latency to find buried food confirming the importance of Nrxn3 in inhibitory synaptic transmission in olfactory bulb (Aoto et al., 2015). Hence, a significant amount of effort needs to be directed in investigating the role of Nrxn3 in ASD-related typical and associated symptoms at the preclinical level.

 Nrxn2 KO mouse models

Constitutive and conditional KO mouse models for Nrxn2 gene have produced behavioral manifestations relevant to typical and associated symptoms of ASD, identifying NRNX2 as a potential candidate gene in the etiology of ASD.

Constitutive Nrxn2 KO mouse models

The constitutive deletion of Nrxn2 (only α-neurexins) induced aberrations in various measures of social behavior including social approach, social novelty, and social investigation. The homozygous deletion of Nrxn2 (only α-neurexins) in mice induced deficits in social approach behavior without any impairments in preference for social novelty (Dachtler et al., 2014). However, in the study by Born et al. (2015), these social approach deficits were only observed in female, but not male, Nrxn2α KO mice, indicating plausible sex differences in social approach behavior in Nrxn2α KO mice (Born et al., 2015). Furthermore, in the same study, female Nrxn2α KO mice engaged in less sniffing time with a conspecific mouse, indicating reduced social investigative behavior (Born et al., 2015). Similar results were produced from the heterozygous deletion of Nrxn2 (only α-neurexins) that yielded mice with deficits in social approach behavior and impaired preference for social novelty (Dachtler et al., 2015). In addition to social behaviors, the impact of constitutive Nrxn2 gene deletion on other ASD-related behaviors including repetitive behavioral patterns was also investigated, albeit to a much lesser extent. Female, but not male, Nrxn2α KO mice spent more time in self-grooming without any changes in frequency of grooming bouts suggesting sex-dependent role for Nrxn2 in behavioral repetition (Born et al., 2015).

The impact of a constitutive deletion of Nrxn2 gene on associated symptoms of ASD including anxiety behavior and cognitive behaviors has also been investigated. Nrxn2α KO mice exhibited anxiogenic behavior in paradigms that exploit the natural aversion of mice to exposed areas including open field, elevated plus maze, and light/dark box tests (Dachtler et al., 2014; Born et al., 2015). Interestingly, heterozygous deletion of Nrxn2 (only α-neurexins) did not induce anxiogenic behavior in mice in the open field or elevated plus maze test (Dachtler et al., 2015). Finally, Nrxn2 gene deletion did not have any effect on cognitive behaviors including information processing and various types of memory function (spatial and working; Dachtler et al., 2014; Born et al., 2015; Dachtler et al., 2015).

 Conditional Nrxn2 KO mouse models

The rationale for generating cKO mouse models is that neurexins can have distinct fundamental roles in different synapses highlighting their diverse role in synaptic transmission, circuit function and potentially, behavioral regulation (Chen et al., 2017). In one study, conditional deletion of Nrxn2 gene in Emx1-positive cells in the cortex and hippocampus induced social impairments and repetitive behavioral patterns, which is similar to findings obtained from constitutive KO mouse models (Haile et al., 2022). In this study, female, but not male, Nrxn2 KO mice exhibited social approach deficits as evidenced by lack of preference between peer and novel object in the 3-chamber social approach task (Haile et al., 2022). Furthermore, male Nrxn2 KO mice exhibited increased preference for non-social cues and a decreased peer/object ratio was observed in both male and female Nrxn2 KO mice indicating social approach deficits in both sexes (Haile et al., 2022). In the domain of repetitive behaviors, male, but not female, Nrxn2 KO mice exhibited increased nestlet shredding behavior without any impairments in other measures of repetitive behaviors including self-grooming, jumping and marbles buried; however, these findings were not accompanied by ASD-related associated symptoms including anxiety-like behavior and working memory deficits (Haile et al., 2022). Another study analyzed hippocampal-specific deletion of Nrxn2 gene on day 24 postpartum (dpp; Lin et al., 2023). This group did not observe alterations in open field test, fear conditioning or passive avoidance tests, but a small impairment in the rotarod test was observed in Nrxn2 cKO mice (Lin et al., 2023). Interestingly, the Nrxn2 cKO mice were able to acquire the location of hidden platform in the water T-maze test as quickly as the WT littermates but exhibited reversal learning deficits suggesting a role for hippocampal Nrxn2 in cognitive flexibility (Lin et al., 2023). Thus, Nrxn2 gene deletion induced specific, rather than generalized, effects on cognitive behaviors. Considering that cognitive inflexibility has been documented in ASD (South et al., 2012; Lecavalier et al., 2020), Nrxn2 gene deletion from the hippocampus can recapitulate some, but not all, of cognitive deficits of ASD. Overall, these findings begin to identify a role for the deletion of Nrxn2 gene in the manifestation of behavioral aberrations that are typical and associated with ASD pathophysiology.

 Future directions

The current work highlights neurexin mutations in ASD and how these mutations can contribute to impairments in synaptic transmission, leading to E/I imbalances and behavioral dysregulation at the circuit level. While the types of neurexin mutations in ASD patients have been deciphered extensively, the outcome of those genetic mutations on protein expression of neurexins in different brain regions has not been thoroughly investigated. These investigations are important in elucidating novel circuit mechanisms though which altered neurexin expression can induce behavioral deficits in ASD patients.

An extensive effort has been undertaken in elucidating the delineation of the heterogenous function of neurexin genes in synaptic physiology. Studies focused on synaptic density, morphology, and transmission have demonstrated that Nrxn2 in hippocampal circuits has a unique and completely opposite role from the currently understood functions of Nrxn1 and Nrxn3. Moreover, these recent findings have transformed previous understandings of neurexins that these SAMs are redundant or have a canonical role. While this presents an exciting prospective avenue of research there are still several gaps in our understanding of the behavioral implications of neurexin deletion in specific circuits in mouse models. Despite the prevalence of NRXN3 mutations in ASD patients (Vaags et al., 2012; Wang et al., 2018; Yuan et al., 2018), there is very little data regarding the effects of Nrxn3 mutations in animal models on behavioral abnormalities reminiscent of ASD. Animal models for Nrxn1 and Nrxn2 genes provide a strong argument for role of disruption of neurexin function in social behavioral and communication deficits that represent the classical symptoms of ASD. More importantly, NRXN1 mutations have been reported in children with speech and language impairments (Brignell et al., 2018). Such clinical findings demonstrate the translational validity of these preclinical models in unravelling novel genetic mechanisms underlying socio-communications impairments in ASD. On the other hand, role of neurexins in repetitive behaviors appears to be more limited with studies reporting significant effect of neurexin deletion on some, but not all, of measures of repetitive behavior in preclinical models. Additionally, the effects of neurexin deletion on cognitive, motor and anxiety behaviors are also limited. Future studies such as conditional deletion of neurexin genes from specific brain regions such as the amygdala that controls social behavior (Felix-Ortiz and Tye, 2014), anxiety (Duvarci and Pare, 2014) and cognitive functions (McGaugh, 2004) would be warranted to ascertain a role for neurexins in ASD-related behaviors. This would be important in the case of Nrxn1 and Nrxn3 since there are few studies (or none) that investigated the effects of conditional deletion of either Nrxn1 or Nrxn3 genes on classical and associated behaviors reminiscent of ASD. In contrast, significant milestones have been achieved in determining the effects of conditional deletion of Nrxn2 gene on ASD-related behaviors (Haile et al., 2022; Lin et al., 2023). Nevertheless, these shortcomings do not undermine the contribution of neurexins to ASD pathophysiology since one animal model cannot recapitulate all the behavioral symptoms of ASD. Furthermore, the conditional deletion of all three neurexin genes on circuit-specific behaviors in the hippocampus or brain regions relevant to ASD pathophysiology needs to be thoroughly investigated. The mutations in neurexin genes can play an essential role in elucidating specific pathways underlying ASD endophenotypes and can aid in the development of druggable targets at the synapses. Moreover, future studies in studying neurexin-glial interactions, the role of sex in neurexin-dependent behaviors, and their role in genetic mechanisms underlying comorbidities will be crucial for deciphering the role of neurexins in ASD pathophysiology.

 Author contributions

SK, MTH, and LYC: writing and editing. MTH: compiled supplementary data and made table. LYC: supervision. All authors contributed to the article and approved the submitted version.

 Funding

This work was supported by the UCI School of Medicine Startup fund (GF15247 to LYC).

 Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

 Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

 Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnmol.2023.1125087/full#supplementary-material

 References ADDM and CDC (2014). Prevalence of autism spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, United States, 2010. MMWR Surveill. Summ. 63, 1–21. Anderson G. R. Aoto J. Tabuchi K. Földy C. Covy J. Yee A. X. . (2015). β-Neurexins control neural circuits by regulating synaptic endocannabinoid signaling. Cells 162, 593–606. doi: 10.1016/j.cell.2015.06.056, PMID: 26213384 Aoto J. Földy C. Ilcus S. M. C. Tabuchi K. Südhof T. C. (2015). Distinct circuit-dependent functions of presynaptic neurexin-3 at GABAergic and glutamatergic synapses. Nat. Neurosci. 18, 997–1007. doi: 10.1038/nn.4037, PMID: 26030848 Aoto J. Martinelli D. C. Malenka R. C. Tabuchi K. Südhof T. C. (2013). Presynaptic neurexin-3 alternative splicing trans-synaptically controls postsynaptic AMPA receptor trafficking. Cells 154, 75–88. doi: 10.1016/j.cell.2013.05.060, PMID: 23827676 Armstrong E. C. Caruso A. Servadio M. Andreae L. C. Trezza V. Scattoni M. L. . (2020). Assessing the developmental trajectory of mouse models of neurodevelopmental disorders: social and communication deficits in mice with Neurexin 1α deletion. Genes Brain Behav. 19:e12630. doi: 10.1111/gbb.12630, PMID: 31823470 Autism and Developmental Disabilities Monitoring Network Surveillance Year 2008 Principal Investigators and Centers for Disease Control and Prevention (2012). Prevalence of autism spectrum disorders--autism and developmental disabilities monitoring network, 14 sites, United States, 2008. MMWR Surveill. Summ. 61, 1–19. Baio J. Wiggins L. Christensen D. L. Maenner M. J. Daniels J. Warren Z. . (2018). Prevalence of autism Spectrum disorder among children aged 8 years — autism and developmental disabilities monitoring network, 11 sites, United States, 2014. MMWR CDC Surveill. Summ. 67, 1–23. doi: 10.15585/mmwr.ss6706a1, PMID: 29701730 Bargmann C. I. (2012). Beyond the connectome: how neuromodulators shape neural circuits. Bioessays 34, 458–465. doi: 10.1002/bies.201100185, PMID: 22396302 Bargmann C. I. Marder E. (2013). From the connectome to brain function. Nat. Methods 10, 483–490. doi: 10.1038/nmeth.2451 Baxter A. J. Brugha T. S. Erskine H. E. Scheurer R. W. Vos T. Scott J. G. (2015). The epidemiology and global burden of autism spectrum disorders. Psychol. Med. 45, 601–613. doi: 10.1017/S003329171400172X Boncinelli E. Gulisano M. Spada F. Broccoli V. (1995). Emx and Otx gene expression in the developing mouse brain. Ciba Found. Symp. 193:117, 100–116. Born G. Grayton H. M. Langhorst H. Dudanova I. Rohlmann A. Woodward B. W. . (2015). Genetic targeting of NRXN2 in mice unveils role in excitatory cortical synapse function and social behaviors. Front. Synaptic Neurosci. 7:3. doi: 10.3389/fnsyn.2015.00003 Bourgeron T. (2015). From the genetic architecture to synaptic plasticity in autism spectrum disorder. Nat. Rev. Neurosci. 16, 551–563. doi: 10.1038/nrn3992, PMID: 26289574 Bourgeron T. (2016). Current knowledge on the genetics of autism and propositions for future research. C. R. Biol. 339, 300–307. doi: 10.1016/j.crvi.2016.05.004, PMID: 27289453 Boyle M. I. Jespersgaard C. Nazaryan L. Ravn K. Brøndum-Nielsen K. Bisgaard A. M. . (2015). Deletion of 11q12.3-11q13.1 in a patient with intellectual disability and childhood facial features resembling Cornelia de Lange syndrome. Gene 572, 130–134. doi: 10.1016/j.gene.2015.07.016, PMID: 26164757 Brignell A. St John M. Boys A. Bruce A. Dinale C. Pigdon L. . (2018). Characterization of speech and language phenotype in children withNRXN1deletions. Am. J. Med. Genet. B Neuropsychiatr. Genet. 177, 700–708. doi: 10.1002/ajmg.b.32664 Carlson G. C. (2012). Glutamate receptor dysfunction and drug targets across models of autism spectrum disorders. Pharmacol. Biochem. Behav. 100, 850–854. doi: 10.1016/j.pbb.2011.02.003, PMID: 21315104 Carter M. T. Scherer S. W. (2013). Autism spectrum disorder in the genetics clinic: a review. Clin. Genet. 83, 399–407. doi: 10.1111/cge.12101, PMID: 23425232 Chen L. Y. Jiang M. Zhang B. Gokce O. Südhof T. C. (2017). Conditional deletion of all neurexins defines diversity of essential synaptic organizer functions for neurexins. Neuron 94, 611–625.e4. doi: 10.1016/j.neuron.2017.04.011, PMID: 28472659 Chih B. Engelman H. Scheiffele P. (2005). Control of excitatory and inhibitory synapse formation by neuroligins. Science 307, 1324–1328. doi: 10.1126/science.1107470 Christensen D. L. Baio J. van Naarden Braun K. Bilder D. Charles J. Constantino J. N. . (2016). Prevalence and characteristics of autism Spectrum disorder among children aged 8 years — autism and developmental disabilities monitoring network, 11 sites, United States, 2012. MMWR CDC Surveill. Summ. 65, 1–23. doi: 10.15585/mmwr.ss6503a1, PMID: 27031587 Culotta L. Penzes P. (2020). Exploring the mechanisms underlying excitation/inhibition imbalance in human iPSC-derived models of ASD. Mol. Autism. 11:32. doi: 10.1186/s13229-020-00339-0, PMID: 32393347 Dachtler J. Glasper J. Cohen R. N. Ivorra J. L. Swiffen D. J. Jackson A. J. . (2014). Deletion of α-neurexin II results in autism-related behaviors in mice. Transl. Psychiatry 4:e484. doi: 10.1038/tp.2014.123, PMID: 25423136 Dachtler J. Ivorra J. L. Rowland T. E. Lever C. Rodgers R. J. Clapcote S. J. (2015). Heterozygous deletion of α-neurexin I or α-neurexin II results in behaviors relevant to autism and schizophrenia. Behav. Neurosci. 129, 765–776. doi: 10.1037/bne0000108, PMID: 26595880 Dai J. Aoto J. Südhof T. C. (2019). Alternative splicing of presynaptic neurexins differentially controls postsynaptic NMDA and AMPA receptor responses. Neuron 102, 993–1008.e5. doi: 10.1016/j.neuron.2019.03.032, PMID: 31005376 de Wit J. Sylwestrak E. O'Sullivan M. L. Otto S. Tiglio K. Savas J. N. . (2009). LRRTM2 interacts with Neurexin1 and regulates excitatory synapse formation. Neuron 64, 799–806. doi: 10.1016/j.neuron.2009.12.019, PMID: 20064388 Dean C. Scholl F. G. Choih J. DeMaria S. Berger J. Isacoff E. . (2003). Neurexin mediates the assembly of presynaptic terminals. Nat. Neurosci. 6, 708–716. doi: 10.1038/nn1074, PMID: 12796785 Di Cristo G. Chattopadhyaya B. (2020). Development of neuronal circuits: from synaptogenesis to synapse plasticity. Handb. Clin. Neurol. 173, 43–53. doi: 10.1016/B978-0-444-64150-2.00005-8, PMID: 32958189 Ducrot C. de Carvalho G. Delignat-Lavaud B. (2021). Neurexins regulate GABA co-release by dopamine neurons. bioRxiv. doi: 10.1101/2021.10.17.464666 Duvarci S. Pare D. (2014). Amygdala microcircuits controlling learned fear. Neuron 82, 966–980. doi: 10.1016/j.neuron.2014.04.042, PMID: 24908482 Etherton M. R. Blaiss C. A. Powell C. M. Südhof T. C. (2009). Mouse neurexin-1alpha deletion causes correlated electrophysiological and behavioral changes consistent with cognitive impairments. Proc. Natl. Acad. Sci. U. S. A. 106, 17998–18003. doi: 10.1073/pnas.0910297106, PMID: 19822762 Fatemi S. H. Reutiman T. J. Folsom T. D. Rooney R. J. Patel D. H. Thuras P. D. (2010). mRNA and protein levels for GABAAalpha4, alpha5, beta1 and GABABR1 receptors are altered in brains from subjects with autism. J. Autism Dev. Disord. 40, 743–750. doi: 10.1007/s10803-009-0924-z, PMID: 20066485 Felix-Ortiz A. C. Tye K. M. (2014). Amygdala inputs to the ventral hippocampus bidirectionally modulate social behavior. J. Neurosci. 34, 586–595. doi: 10.1523/JNEUROSCI.4257-13.2014, PMID: 24403157 Folstein S. E. Rosen-Sheidley B. (2001). Genetics of autism: complex aetiology for a heterogeneous disorder. Nat. Rev. Genet. 2, 943–955. doi: 10.1038/35103559, PMID: 11733747 Gauthier J. Siddiqui T. J. Huashan P. Yokomaku D. Hamdan F. F. Champagne N. . (2011). Truncating mutations in NRXN2 and NRXN1 in autism spectrum disorders and schizophrenia. Hum. Genet. 130, 563–573. doi: 10.1007/s00439-011-0975-z, PMID: 21424692 Glessner J. T. Wang K. Cai G. Korvatska O. Kim C. E. Wood S. . (2009). Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature 459, 569–573. doi: 10.1038/nature07953, PMID: 19404257 Gorski J. A. Talley T. Qiu M. Puelles L. Rubenstein J. L. R. Jones K. R. (2002). Cortical excitatory neurons and glia, but not GABAergic neurons, are produced in the Emx1-expressing lineage. J. Neurosci. 22, 6309–6314. doi: 10.1523/JNEUROSCI.22-15-06309.2002, PMID: 12151506 Graf E. R. Zhang X. Z. Jin S. X. Linhoff M. W. Craig A. M. (2004). Neurexins induce differentiation of GABA and glutamate postsynaptic specializations via neuroligins. Cells 119, 1013–1026. doi: 10.1016/j.cell.2004.11.035, PMID: 15620359 Grayton H. M. Missler M. Collier D. A. Fernandes C. (2013). Altered social behaviours in neurexin 1α knockout mice resemble core symptoms in neurodevelopmental disorders. PLoS One 8:e67114. doi: 10.1371/journal.pone.0067114, PMID: 23840597 Haile M. T. Khoja S. de Carvalho G. Hunt R. F. Chen L. Y. (2022). Conditional deletion of Neurexin-2 alters neuronal network activity in hippocampal circuitries and leads to spontaneous seizures. Res. Sq. doi: 10.21203/rs.3.rs-2265451/v1 Harkin L. F. Lindsay S. J. Xu Y. Alzu'bi A. Ferrara A. Gullon E. A. . (2017). Neurexins 1-3 each have a distinct pattern of expression in the early developing human cerebral cortex. Cereb. Cortex 27, 216–232. doi: 10.1093/cercor/bhw394, PMID: 28013231 He J. L. Oeltzschner G. Mikkelsen M. Deronda A. Harris A. D. Crocetti D. . (2021). Region-specific elevations of glutamate + glutamine correlate with the sensory symptoms of autism spectrum disorders. Transl. Psychiatry 11:411. doi: 10.1038/s41398-021-01525-1, PMID: 34326312 Huguet G. Ey E. Bourgeron T. (2013). The genetic landscapes of autism spectrum disorders. Annu. Rev. Genomics Hum. Genet. 14, 191–213. doi: 10.1146/annurev-genom-091212-153431 Ishizuka K. Yoshida T. Kawabata T. Imai A. Mori H. Kimura H. . (2020). Functional characterization of rare NRXN1 variants identified in autism spectrum disorders and schizophrenia. J. Neurodev. Disord. 12:25. doi: 10.1186/s11689-020-09325-2, PMID: 32942984 Jang S. Lee H. Kim E. (2017). Synaptic adhesion molecules and excitatory synaptic transmission. Curr. Opin. Neurobiol. 45, 45–50. doi: 10.1016/j.conb.2017.03.005 Jeste S. S. Tuchman R. (2015). Autism spectrum disorder and epilepsy: two sides of the same coin? J. Child Neurol. 30, 1963–1971. doi: 10.1177/0883073815601501, PMID: 26374786 Kang Y. Zhang X. Z. Dobie F. Wu H. Craig A. M. (2008). Induction of GABAergic postsynaptic differentiation by alpha-neurexins. J. Biol. Chem. 283, 2323–2334. doi: 10.1074/jbc.M703957200, PMID: 18006501 Kattenstroth G. Tantalaki E. Südhof T. C. Gottmann K. Missler M. (2004). Postsynaptic N-methyl-D-aspartate receptor function requires alpha-neurexins. Proc. Natl. Acad. Sci. U. S. A. 101, 2607–2612. doi: 10.1073/pnas.0308626100, PMID: 14983056 Kim H.-G. Kishikawa S. Higgins A. W. Seong I. S. Donovan D. J. Shen Y. . (2008). Disruption of neurexin 1 associated with autism spectrum disorder. Am. J. Hum. Genet. 82, 199–207. doi: 10.1016/j.ajhg.2007.09.011, PMID: 18179900 Kim H. Y. Um J. W. Ko J. (2021). Proper synaptic adhesion signaling in the control of neural circuit architecture and brain function. Prog. Neurobiol. 200:101983. doi: 10.1016/j.pneurobio.2020.101983, PMID: 33422662 Lai M.-C. Lombardo M. V. Baron-Cohen S. (2014). Autism. Lancet 383, 896–910. doi: 10.1016/S0140-6736(13)61539-1 Landa R. J. (2008). Diagnosis of autism spectrum disorders in the first 3 years of life. Nat. Clin. Pract. Neurol. 4, 138–147. doi: 10.1038/ncpneuro0731 Lavelle T. A. Weinstein M. C. Newhouse J. P. Munir K. Kuhlthau K. A. Prosser L. A. (2014). Economic burden of childhood autism spectrum disorders. Pediatrics 133, e520–e529. doi: 10.1542/peds.2013-0763, PMID: 24515505 Lecavalier L. Bodfish J. Harrop C. Whitten A. Jones D. Pritchett J. . (2020). Development of the behavioral inflexibility scale for children with autism Spectrum disorder and other developmental disabilities. Autism Res. 13, 489–499. doi: 10.1002/aur.2257, PMID: 31904198 Leigh J. P. Du J. (2015). Brief report: forecasting the economic burden of autism in 2015 and 2025 in the United States. J. Autism Dev. Disord. 45, 4135–4139. doi: 10.1007/s10803-015-2521-7, PMID: 26183723 Lin P.-Y. Chen L. Y. Jiang M. Trotter J. H. Seigneur E. Südhof T. C. (2023). Neurexin-2: an inhibitory neurexin that restricts excitatory synapse formation in the hippocampus. Sci. Adv. 9:add8856. doi: 10.1126/sciadv.add8856, PMID: 36608123 Luo F. Jiang M. Südhof T. C. Südhof T. C. (2020). Neurexins cluster ca(2+) channels within the presynaptic active zone. EMBO J. 39:e103208. doi: 10.15252/embj.2019103208, PMID: 32134527 Luo F. Sclip A. Merrill S. Südhof T. C. (2021). Neurexins regulate presynaptic GABAB-receptors at central synapses. Nat. Commun. 12:2380. doi: 10.1038/s41467-021-22753-5, PMID: 33888718 Maenner M. J. Shaw K. A. Bakian A. V. Bilder D. A. Durkin M. S. Esler A. . (2021). Prevalence and characteristics of autism Spectrum disorder among children aged 8 years — autism and developmental disabilities monitoring network, 11 sites, United States, 2018. MMWR CDC Surveill. Summ. 70, 1–16. doi: 10.15585/mmwr.ss7011a1, PMID: 34855725 Marshall C. R. Noor A. Vincent J. B. Lionel A. C. Feuk L. Skaug J. . (2008). Structural variation of chromosomes in autism spectrum disorder. Am. J. Hum. Genet. 82, 477–488. doi: 10.1016/j.ajhg.2007.12.009, PMID: 18252227 Masini E. Loi E. Vega-Benedetti A. F. Carta M. Doneddu G. Fadda R. . (2020). An overview of the main genetic, epigenetic and environmental factors involved in autism spectrum disorder focusing on synaptic activity. Int. J. Mol. Sci. 21:8290. doi: 10.3390/ijms21218290, PMID: 33167418 McGaugh J. L. (2004). The amygdala modulates the consolidation of memories of emotionally arousing experiences. Annu. Rev. Neurosci. 27, 1–28. doi: 10.1146/annurev.neuro.27.070203.144157, PMID: 15217324 Missler M. Südhof T. C. (1998). Neurexins: three genes and 1001 products. Trends Genet. 14, 20–26. doi: 10.1016/S0168-9525(97)01324-3, PMID: 9448462 Missler M. Südhof T. C. Biederer T. (2012). Synaptic cell adhesion. Cold Spring Harb. Perspect. Biol. 4:a005694. doi: 10.1101/cshperspect.a005694, PMID: 22278667 Missler M. Zhang W. Rohlmann A. Kattenstroth G. Hammer R. E. Gottmann K. . (2003). Alpha-neurexins couple Ca2+ channels to synaptic vesicle exocytosis. Nature 423, 939–948. doi: 10.1038/nature01755, PMID: 12827191 Mohrmann I. Gillessen-Kaesbach G. Siebert R. Caliebe A. Hellenbroich Y. (2011). A de novo 0.57 Mb microdeletion in chromosome 11q13.1 in a patient with speech problems, autistic traits, dysmorphic features and multiple endocrine neoplasia type 1. Eur. J. Med. Genet. 54, e461–e464. doi: 10.1016/j.ejmg.2011.04.006, PMID: 21600320 Nam C. I. Chen L. (2005). Postsynaptic assembly induced by neurexin-neuroligin interaction and neurotransmitter. Proc. Natl. Acad. Sci. U. S. A. 102, 6137–6142. doi: 10.1073/pnas.0502038102, PMID: 15837930 Nurk S. Koren S. Rhie A. Rautiainen M. Bzikadze A. V. Mikheenko A. . (2022). The complete sequence of a human genome. Science 376, 44–53. doi: 10.1126/science.abj6987, PMID: 35357919 Oliveira B. Mitjans M. Nitsche M. A. Kuo M. F. Ehrenreich H. (2018). Excitation-inhibition dysbalance as predictor of autistic phenotypes. J. Psychiatr. Res. 104, 96–99. doi: 10.1016/j.jpsychires.2018.06.004, PMID: 30015265 Onay H. Kacamak D. Kavasoglu A. N. Akgun B. Yalcinli M. Kose S. . (2016). Mutation analysis of the NRXN1 gene in autism spectrum disorders. Balkan J Med Genet 19, 17–22. doi: 10.1515/bjmg-2016-0031, PMID: 28289584 Persico A. M. Bourgeron T. (2006). Searching for ways out of the autism maze: genetic, epigenetic and environmental clues. Trends Neurosci. 29, 349–358. doi: 10.1016/j.tins.2006.05.010, PMID: 16808981 Pervolaraki E. Tyson A. L. Pibiri F. Poulter S. L. Reichelt A. C. Rodgers R. J. . (2019). The within-subject application of diffusion tensor MRI and CLARITY reveals brain structural changes in Nrxn2 deletion mice. Mol. Autism. 10:8. doi: 10.1186/s13229-019-0261-9, PMID: 30858964 Pettem K. L. Yokomaku D. Luo L. Linhoff M. W. Prasad T. Connor S. A. . (2013). The specific α-neurexin interactor calsyntenin-3 promotes excitatory and inhibitory synapse development. Neuron 80, 113–128. doi: 10.1016/j.neuron.2013.07.016, PMID: 24094106 Pinto D. Pagnamenta A. T. Klei L. Anney R. Merico D. Regan R. . (2010). Functional impact of global rare copy number variation in autism spectrum disorders. Nature 466, 368–372. doi: 10.1038/nature09146, PMID: 20531469 Port R. G. Oberman L. M. Roberts T. P. (2019). Revisiting the excitation/inhibition imbalance hypothesis of ASD through a clinical lens. Br. J. Radiol. 92:20180944. doi: 10.1259/bjr.20180944, PMID: 31124710 Rabaneda L. G. Robles-Lanuza E. Nieto-González J. L. Scholl F. G. (2014). Neurexin dysfunction in adult neurons results in autistic-like behavior in mice. Cell Rep. 8, 338–346. doi: 10.1016/j.celrep.2014.06.022, PMID: 25017069 Reichelt A. C. Rodgers R. J. Clapcote S. J. (2012). The role of neurexins in schizophrenia and autistic spectrum disorder. Neuropharmacology 62, 1519–1526. doi: 10.1016/j.neuropharm.2011.01.024, PMID: 21262241 Reissner C. Runkel F. Missler M. (2013). Neurexins. Genome Biol. 14:213. doi: 10.1186/gb-2013-14-9-213, PMID: 24083347 Robertson C. E. Ratai E.-M. Kanwisher N. (2016). Reduced gabaergic action in the autistic brain. Curr. Biol. 26, 80–85. doi: 10.1016/j.cub.2015.11.019, PMID: 26711497 Rochtus A. M. Trowbridge S. Goldstein R. D. Sheidley B. R. Prabhu S. P. Haynes R. . (2019). Mutations in NRXN1 and NRXN2 in a patient with early-onset epileptic encephalopathy and respiratory depression. Mol. Case Stud. 5:a003442. doi: 10.1101/mcs.a003442, PMID: 30709877 Rowen L. Young J. Birditt B. Kaur A. Madan A. Philipps D. L. . (2002). Analysis of the human neurexin genes: alternative splicing and the generation of protein diversity. Genomics 79, 587–597. doi: 10.1006/geno.2002.6734, PMID: 11944992 Rubenstein J. L. R. Merzenich M. M. (2003). Model of autism: increased ratio of excitation/inhibition in key neural systems. Genes Brain Behav. 2, 255–267. doi: 10.1034/j.1601-183X.2003.00037.x, PMID: 14606691 Rylaarsdam L. Guemez-Gamboa A. (2019). Genetic causes and modifiers of autism spectrum disorder. Front. Cell. Neurosci. 13:385. doi: 10.3389/fncel.2019.00385, PMID: 31481879 Sanes J. R. Zipursky S. L. (2020). Synaptic specificity, recognition molecules, and assembly of neural circuits. Cells 181, 536–556. doi: 10.1016/j.cell.2020.04.008, PMID: 32359437 Schür R. R. Draisma L. W. R. Wijnen J. P. Boks M. P. Koevoets M. G. J. C. Joëls M. . (2016). Brain GABA levels across psychiatric disorders: a systematic literature review and meta-analysis of (1) H-MRS studies. Hum. Brain Mapp. 37, 3337–3352. doi: 10.1002/hbm.23244, PMID: 27145016 Sebat J. Lakshmi B. Malhotra D. Troge J. Lese-Martin C. Walsh T. . (2007). Strong association of de novo copy number mutations with autism. Science 316, 445–449. doi: 10.1126/science.1138659, PMID: 17363630 Shinohe A. Hashimoto K. Nakamura K. Tsujii M. Iwata Y. Tsuchiya K. J. . (2006). Increased serum levels of glutamate in adult patients with autism. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 30, 1472–1477. doi: 10.1016/j.pnpbp.2006.06.013, PMID: 16863675 Siddiqui T. J. Pancaroglu R. Kang Y. Rooyakkers A. Craig A. M. (2010). LRRTMs and neuroligins bind neurexins with a differential code to cooperate in glutamate synapse development. J. Neurosci. 30, 7495–7506. doi: 10.1523/JNEUROSCI.0470-10.2010, PMID: 20519524 Sons M. S. Busche N. Strenzke N. Moser T. Ernsberger U. Mooren F. C. . (2006). Alpha-Neurexins are required for efficient transmitter release and synaptic homeostasis at the mouse neuromuscular junction. Neuroscience 138, 433–446. doi: 10.1016/j.neuroscience.2005.11.040, PMID: 16406382 South M. Newton T. Chamberlain P. D. (2012). Delayed reversal learning and association with repetitive behavior in autism spectrum disorders. Autism Res. 5, 398–406. doi: 10.1002/aur.1255, PMID: 23097376 Spooren W. Lindemann L. Ghosh A. Santarelli L. (2012). Synapse dysfunction in autism: a molecular medicine approach to drug discovery in neurodevelopmental disorders. Trends Pharmacol. Sci. 33, 669–684. doi: 10.1016/j.tips.2012.09.004, PMID: 23084458 Sterky F. H. Trotter J. H. Lee S. J. Recktenwald C. V. du X. Zhou B. . (2017). Carbonic anhydrase-related protein CA10 is an evolutionarily conserved pan-neurexin ligand. Proc. Natl. Acad. Sci. U. S. A. 114, E1253–E1262. doi: 10.1073/pnas.1621321114, PMID: 28154140 Südhof T. C. (2018). Towards an understanding of synapse formation. Neuron 100, 276–293. doi: 10.1016/j.neuron.2018.09.040, PMID: 30359597 Südhof T. C. (2021). The cell biology of synapse formation. J. Cell Biol. 220:3052. doi: 10.1083/jcb.202103052, PMID: 34086051 Tabuchi K. Südhof T. C. (2002). Structure and evolution of neurexin genes: insight into the mechanism of alternative splicing. Genomics 79, 849–859. doi: 10.1006/geno.2002.6780, PMID: 12036300 Treutlein B. Gokce O. Quake S. R. Südhof T. C. (2014). Cartography of neurexin alternative splicing mapped by single-molecule long-read mRNA sequencing. Proc. Natl. Acad. Sci. U. S. A. 111, E1291–E1299. doi: 10.1073/pnas.1403244111, PMID: 24639501 Tuchman R. Cuccaro M. Alessandri M. (2010). Autism and epilepsy: historical perspective. Brain Dev. 32, 709–718. doi: 10.1016/j.braindev.2010.04.008, PMID: 20510557 Ullrich B. Ushkaryov Y. A. Südhof T. C. (1995). Cartography of neurexins: more than 1000 isoforms generated by alternative splicing and expressed in distinct subsets of neurons. Neuron 14, 497–507. doi: 10.1016/0896-6273(95)90306-2, PMID: 7695896 Ushkaryov Y. A. Hata Y. Ichtchenko K. Moomaw C. Afendis S. Slaughter C. A. . (1994). Conserved domain structure of beta-neurexins. Unusual cleaved signal sequences in receptor-like neuronal cell-surface proteins. J. Biol. Chem. 269, 11987–11992. doi: 10.1016/S0021-9258(17)32671-6, PMID: 8163501 Ushkaryov Y. A. Petrenko A. G. Geppert M. Südhof T. C. (1992). Neurexins: synaptic cell surface proteins related to the alpha-latrotoxin receptor and laminin. Science 257, 50–56. doi: 10.1126/science.1621094, PMID: 1621094 Ushkaryov Y. A. Südhof T. C. (1993). Neurexin III alpha: extensive alternative splicing generates membrane-bound and soluble forms. Proc. Natl. Acad. Sci. U. S. A. 90, 6410–6414. doi: 10.1073/pnas.90.14.6410, PMID: 8341647 Vaags A. K. Lionel A. C. Sato D. Goodenberger M. K. Stein Q. P. Curran S. . (2012). Rare deletions at the neurexin 3 locus in autism spectrum disorder. Am. J. Hum. Genet. 90, 133–141. doi: 10.1016/j.ajhg.2011.11.025, PMID: 22209245 Veenstra-Vander Weele J. Cook E. H. (2004). Molecular genetics of autism spectrum disorder. Mol. Psychiatry 9, 819–832. doi: 10.1038/sj.mp.4001505 Wang J. Gong J. Li L. Chen Y. Liu L. Gu H. T. . (2018). Neurexin gene family variants as risk factors for autism spectrum disorder. Autism Res. 11, 37–43. doi: 10.1002/aur.1881, PMID: 29045040 Williams M. E. de Wit J. Ghosh A. (2010). Molecular mechanisms of synaptic specificity in developing neural circuits. Neuron 68, 9–18. doi: 10.1016/j.neuron.2010.09.007, PMID: 20920787 Yuan H. Wang Q. Liu Y. Yang W. He Y. Gusella J. F. . (2018). A rare exonic NRXN3 deletion segregating with neurodevelopmental and neuropsychiatric conditions in a three-generation Chinese family. Am. J. Med. Genet. B Neuropsychiatr. Genet. 177, 589–595. doi: 10.1002/ajmg.b.32673, PMID: 30076746 Zahir F. R. Baross A. Delaney A. D. Eydoux P. Fernandes N. D. Pugh T. . (2008). A patient with vertebral, cognitive and behavioural abnormalities and a de novo deletion of NRXN1alpha. J. Med. Genet. 45, 239–243. doi: 10.1136/jmg.2007.054437, PMID: 18057082 Zhang W. Rohlmann A. Sargsyan V. Aramuni G. Hammer R. E. Südhof T. C. . (2005). Extracellular domains of alpha-neurexins participate in regulating synaptic transmission by selectively affecting N-and P/Q-type Ca2+ channels. J. Neurosci. 25, 4330–4342. doi: 10.1523/JNEUROSCI.0497-05.2005, PMID: 15858059